The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10180 malaria professionals are enjoying the free benefits of MalariaWorld today

falciparum malaria

NOT Open Access | Tumour necrosis factor alpha promoter polymorphism, TNF-238 is associated with severe clinical outcome of falciparum malaria in Ibadan southwest Nigeria

July 2, 2016 - 16:27 -- NOT Open Access
Subulade A. Olaniyan, Olukemi K. Amodu, Adekunle A. Bakare, Marita Troye-Blomberg, Olayemi O. Omotade, Kirk A. Rockett
Acta Tropica, Volume 161, September 2016, Pages 62–67

Tumour necrosis factor (TNF) – α has been shown to play an important role in the pathogenesis of falciparum malaria.


Clinical illness and outcomes in Nigerian children with late-appearing anaemia after artemisinin-based combination treatments of uncomplicated falciparum malaria

June 8, 2016 - 15:59 -- Open Access
Sowunmi A, Akano K, Ayede A, Ntadom G, Aderoyeje T, Adewoye E, Fatunmbi B
BMC Infectious Diseases 2016, 16:240 (1 June 2016)

This was an open label study with the main objectives of evaluating the clinical features, the risk factors for, the temporal changes in haematocrit and the outcomes of a LAA in malarious children treated with artesunate-amodiaquine (AA), artemether-lumefantrine (AL) or dihydroartemisinin-piperaquine (DHP). 

Field evaluation of a PfHRP-2/pLDH rapid diagnostic test and light microscopy for diagnosis and screening of falciparum malaria during the peak seasonal transmission in an endemic area in Yemen

February 2, 2016 - 18:56 -- Open Access
Lina M. Q. Alareqi, Mohammed A. K. Mahdy, Yee-Ling Lau, Mun-Yik Fong, Rashad Abdul-Ghani, Arwa A. Ali, Fei-Wen Cheong, Rehab Tawfek and Rohela Mahmud
Malaria Journal 2016 15:49, 28 January 2016

The PfHRP-2/pLDH RDT shows high sensitivity for the survey of falciparum malaria even for asymptomatic malaria cases.

Medical Treatment: 

High efficacy of two artemisinin-based combinations: artesunate + sulfadoxine-pyrimethamine and artemether-lumefantrine for falciparum malaria in Yemen

November 18, 2015 - 14:08 -- Open Access
Ahmed Adeel, Niaz Saeed, Rania Nada, et al.
Malaria Journal 2015, 14:449 (14 November 2015)

AS + SP remains the effective drug for uncomplicated falciparum malaria in Yemen.

Medical Treatment: 

Not Open Access | Fitness of artemisinin-resistant Plasmodium falciparum in vitro

July 28, 2015 - 14:33 -- NOT Open Access
Amanda Hott, Matthew S. Tucker, Debora Casandra, Kansas Sparks and Dennis E. Kyle
J. Antimicrob. Chemother. (2015)

We experimentally demonstrate for the first time that artemisinin resistance provides a fitness advantage that is selected for with infrequent exposure to drug, but is lost in the absence of exposure to artemisinin drugs. 

Severe falciparum malaria treated with artesunate complicated by delayed onset haemolysis and acute kidney injury

June 20, 2015 - 08:21 -- Open Access
Katherine Plewes, Md Haider, Hugh W F Kingston, Tsin W Yeo, Aniruddha Ghose, Amir Hossain, Arjen M Dondorp, Gareth D H Turner, Nicholas M Anstey
Malaria Journal 2015, 14:246 (18 June 2015)

This report describes PADH complicated by acute kidney injury in an adult patient living in a malaria hypoendemic region who subsequently required blood transfusions and haemodialysis.

Defining the In Vivo Phenotype of Artemisinin-Resistant Falciparum Malaria: A Modelling Approach

April 30, 2015 - 12:53 -- Open Access
Lisa J. White, Jennifer A. Flegg, Arjen M. Dondorp, et al.
PLoS Med 12(4): e1001823

Characterisation of overlapping distributions of parasite half-lives provides quantitative insight into the relationship between parasite clearance and artemisinin resistance, as well as the predictive value of the 10% cut-off in 'day-3' parasitaemia.

Medical Condition: 

The clinical implications of thrombocytopenia in adults with severe falciparum malaria: a retrospective analysis

April 28, 2015 - 16:44 -- Open Access
Hanson J, Phu N, Day N, et al.
BMC Medicine 2015, 13 :97 (24 April 2015)

The 39 patients (6%) with profound thrombocytopenia (platelet count <20 × 109/L) were more likely to die (odds ratio: 5.00, 95% confidence interval: 2.56 to 9.75) than patients with higher platelet counts, but these high-risk patients could be identified more rapidly with simple bedside clinical assessment. The admission platelet count did not reliably identify the 50 patients (7.7%) with major bleeding during the study.

Impaired Systemic Tetrahydrobiopterin Bioavailability and Increased Dihydrobiopterin in Adult Falciparum Malaria: Association with Disease Severity, Impaired Microvascular Function and Increased Endothelial Activation

March 16, 2015 - 08:47 -- Open Access
Tsin W. Yeo, Daniel A. Lampah, Enny Kenangalem, Emiliana Tjitra, Ric N. Price, J. Brice Weinberg, Keith Hyland, Donald L. Granger, Nicholas M. Anstey
PLoS Pathog 11(3): e1004667

Tetrahydrobiopterin (BH4) is a co-factor required for catalytic activity of nitric oxide synthase (NOS) and amino acid-monooxygenases, including phenylalanine hydroxylase.

Not Open Access | Efficacy and Safety of Triple Combination Therapy With Artesunate-Amodiaquine–Methylene Blue for Falciparum Malaria in Children: A Randomized Controlled Trial in Burkina Faso

February 16, 2015 - 15:42 -- NOT Open Access
Boubacar Coulibaly, Michael Pritsch, Olaf Müller, et al.
J Infect Dis. (2015) 211 (5): 689-697.

The combination of MB with an artemisinin-based combination therapy has been confirmed to be effective against the gametocytes of P. falciparum.


Subscribe to RSS - falciparum malaria